Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Approvals Action
Janssen, BMS, Biogen, CSL boost portfolios
The drugs register has seen a good deal of activity during the week with five new products being approved including new doses of existing drugs.
Pipeline Monitor
First therapy for Duchenne muscular dystrophy
FDA green lights first therapy for Duchenne muscular dystrophy while Opdivo moves towards a sixth indication in Europe and CHMP releases new approval advice.
Debating Point
Reg reform: even if it's good, it's only half the job
As industry braces for three years of regulatory reform, welcome as it may be, the question arises whether, for medicines access it's only half the job that needs to be done.